Assessing and advancing the safety of CRISPR-Cas tools: from DNA to RNA editing.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 36639728.
- Also identified by DOI 10.1038/s41467-023-35886-6 and PMC identifier 9838544.
- Licence recorded as CC BY.
- The licence permits redistribution, so the abstract is shown in full and the full text is available from the publisher.
Abstract
CRISPR-Cas gene editing has revolutionized experimental molecular biology over the past decade and holds great promise for the treatment of human genetic diseases. Here we review the development of CRISPR-Cas9/Cas12/Cas13 nucleases, DNA base editors, prime editors, and RNA base editors, focusing on the assessment and improvement of their editing precision and safety, pushing the limit of editing specificity and efficiency. We summarize the capabilities and limitations of each CRISPR tool from DNA editing to RNA editing, and highlight the opportunities for future improvements and applications in basic research, as well as the therapeutic and clinical considerations for their use in patients.
Medical subject headings
- CRISPR-Cas Systems
- RNA Editing